lutetium Lu 177- Diethylenetriamine Pentaacetic acid-omburtamab (FDA Approval Pending)

Action and Spectrum

Actions and Spectrum  

lutetium Lu 177 is a radioactive isotope of lutetium. It emits beta particles, which are useful for precisely targeting cancer cells for radiation. Diethylenetriamine Penta acetic acid is referred to as DTPA.

It is a chelating substance that binds steadily to lutetium Lu 177. In order to transport and deliver the lutetium to cancer cells, DTPA must first bond with it. 

Monoclonal antibody omburtamab, also called 8H9, is used in medicine. The chemicals or proteins on cancer cells are particularly recognised and bound to by monoclonal antibodies. 

Drug Interaction

Adverse Reaction

None

Black Box Warning

Black Box Warning: 

None 

Contraindication / Caution

Contraindication/Caution:  

Contraindication: 

• It should not be administered to patients with a history of severe allergic reactions or hypersensitivity to any of the drug’s components. 

Caution: 

• Patients with end-stage renal illness or severe renal impairment should use caution since they may be more susceptible to renal toxicity.  
• Patients with pre-existing haematological diseases or impaired bone marrow function should use caution. 

Pregnancy / Lactation

Pregnancy warnings:     

Pregnancy category: N/A 

Lactation: Excretion into human milk is unknown  

Pregnancy Categories:         

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.   

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women. 

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women. 

Category N: There is no data available for the drug under this category.

Pharmacology

Pharmacology  

Localized radiation delivery is made possible by the beta particles in lutetium Lu 177’s short range of tissue penetration. 

Diethylenetriamine Penta acetic acid, or DTPA, functions as a carrier molecule that attaches to the radioactive element lutetium Lu 177 and aids in moving it around the body. 

The drug omburtamab targets the protein B7-H3, which is frequently expressed on neuroblastoma cells. 

Pharmacodynamics 

Limited information available  

Pharmacokinetics 

Limited information available on ADME

Adminstartion

Administration  

lutetium Lu 177- Diethylenetriamine Penta acetic acid-omburtamab is administered through intravenous route to ensure direct delivery into the bloodstream. The drug is typically given as an infusion. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: lutetium Lu 177- Diethylenetriamine Penta acetic acid -omburtamab (FDA Approval Pending) 

Why do we use lutetium Lu 177- Diethylenetriamine Penta acetic acid -omburtamab? 

This drug is used for the treatment of neuroblastoma, a kind of cancer that frequently affects children. The medication is specifically prescribed for the treatment of people with relapsed or resistant neuroblastoma, especially those who have leptomeningeal or central nervous system metastases.